Bromantane
| Category | Compounds |
|---|---|
| Also known as | Ladasten, ADK-709, Bromantan |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | nootropicadaptogenrussian-researchdopaminergic |
Overview
Bromantane (marketed in Russia as Ladasten) is an adamantane-derived small molecule originally developed by Soviet military researchers as an adaptogenic performance aid. Unlike classical stimulants, it is described as having both activating and anxiolytic properties, without the sympathomimetic surge associated with amphetamine-class drugs. Clinical use in Russia includes asthenic disorders.
Pharmacology studies describe bromantane as modulating dopaminergic tone by influencing tyrosine hydroxylase and DOPA decarboxylase expression, effectively increasing dopamine synthesis rather than triggering acute release. It is also reported to affect GABA and serotonin systems, which may explain the combined activating and anxiolytic profile.
Bromantane is widely discussed in nootropic research communities alongside Semax, Selank, Noopept, and Methylene Blue. Although not a peptide, it is commonly catalogued with peptide nootropics because of its origin in the same research tradition.
Structure / Chemistry
Bromantane is N-(4-bromophenyl)adamantan-2-amine, a lipophilic small molecule (molecular weight ~306 g/mol). The adamantane scaffold is shared with amantadine and rimantadine but the pharmacological profile differs substantially.
Mechanism of Action
Proposed mechanisms include upregulation of tyrosine hydroxylase and DOPA decarboxylase in specific brain regions, leading to gradual increases in dopamine synthesis. Additional effects on GABAergic and serotonergic signaling, anti-inflammatory cytokine profiles, and neurosteroid modulation have been described. The combined effect is reported to produce energization with reduced anxiety, distinct from classical psychostimulants.
Research Summary
| Area | Finding | Reference |
|---|---|---|
| Dopamine synthesis | Tyrosine hydroxylase/DDC upregulation | Vakhitova et al., Bull Exp Biol Med 2005 |
| Asthenia | Clinical use in asthenic disorders | Morozov et al., Russian clinical reports |
| Anxiolytic | Combined stimulant-anxiolytic profile | Mikhaylova et al., Bull Exp Biol Med 2007 |
| Adaptogen | Performance under stress in rodents | Grekhova et al., Eksp Klin Farmakol 1995 |
| Immunomodulation | Effects on cytokine profiles | Sergeeva et al., Bull Exp Biol Med 2009 |
Pharmacokinetics
Bromantane is orally active with a plasma half-life reported in multiple hours. Russian clinical protocols have used 50-100 mg daily for limited courses. Specific doses are referenced as trial parameters, not guidance.
Common Discussion Topics
- Distinction from classical stimulants in subjective profile.
- Gradual vs. acute effects via dopamine-synthesis modulation.
- Role as a WADA-banned substance in sports doping.
- Availability and regulatory status outside Russia.
- Combination use with nootropic peptides in research contexts.
Related Compounds
Sourcing research-grade compounds
Obtaining high-purity, research-grade Bromantane requires verified and trusted suppliers with third-party COA testing and transparent sourcing practices.
White Market Peptides — Verified Supplier →Join the discussion
See how the community is discussing Bromantane. Share your experience, ask questions, and explore protocols on PepAtlas.
Related entries
- Methylene Blue— Methylene Blue is a redox-active phenothiazine dye with approved medical uses and nootropic research interest driven by its mitochondrial electron transport activity.
- Noopept— Noopept is a synthetic proline-containing dipeptide nootropic developed in Russia, often discussed as a more potent, orally active analog of piracetam.
- P21 Peptide— P21 is a CNTF-derived tetrapeptide designed to mimic the active region of ciliary neurotrophic factor, studied for neurogenesis and Alzheimer's disease models.
- Selank— A synthetic heptapeptide analog of the immunomodulatory peptide tuftsin, developed in Russia as an anxiolytic and nootropic with additional immunomodulatory properties.
- Semax— A synthetic heptapeptide analog of ACTH(4-10) developed in Russia as a nootropic and neuroprotective agent, studied for cognitive enhancement, stroke recovery, and BDNF modulation.